ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Gross of the placeholder expense ratio and trading costs · not investor results
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1HCA | HCA HEALTHCARE INC | Healthcare | $104.58B | 17.10% |
2IDXX | IDEXX LABORATORIES INC | Healthcare | $54.99B | 8.99% |
3ONC | BEONE MEDICINES LTD | Healthcare | $47.50B | 7.77% |
4NTRA | NATERA INC | Healthcare | $46.83B | 7.66% |
5MTD | METTLER TOLEDO INTERNATIONAL INC | Healthcare | $34.43B | 5.63% |
6DXCM | DEXCOM INC | Healthcare | $30.35B | 4.96% |
7INSM | INSMED INC | Healthcare | $25.90B | 4.24% |
8INCY | INCYTE CORP | Healthcare | $24.81B | 4.06% |
9THC | TENET HEALTHCARE CORP | Healthcare | $22.83B | 3.73% |
10NBIX | NEUROCRINE BIOSCIENCES INC | Healthcare | $17.15B | 2.80% |
11EXEL | EXELIXIS INC | Healthcare | $17.04B | 2.79% |
12PEN | PENUMBRA INC | Healthcare | $12.64B | 2.07% |
13PODD | INSULET CORP | Healthcare | $10.36B | 1.69% |
14MDGL | MADRIGAL PHARMACEUTICALS INC | Healthcare | $9.88B | 1.62% |
15HNGE | HINGE HEALTH INC | Healthcare | $9.83B | 1.61% |
16CORT | CORCEPT THERAPEUTICS INC | Healthcare | $8.07B | 1.32% |
17RYTM | RHYTHM PHARMACEUTICALS INC | Healthcare | $7.62B | 1.25% |
18AXSM | AXSOME THERAPEUTICS INC | Healthcare | $7.59B | 1.24% |
19KNSA | KINIKSA PHARMACEUTICALS INTERNATIONAL PLC | Healthcare | $7.56B | 1.24% |
20CHE | CHEMED CORP | Healthcare | $7.16B | 1.17% |
21CAI | CARIS LIFE SCIENCES INC | Healthcare | $6.87B | 1.12% |
22MIRM | MIRUM PHARMACEUTICALS INC | Healthcare | $6.09B | 1.00% |
23DOCS | DOXIMITY INC | Healthcare | $5.92B | 0.97% |
24LQDA | LIQUIDIA CORP | Healthcare | $5.24B | 0.86% |
25TVTX | TRAVERE THERAPEUTICS INC | Healthcare | $4.95B | 0.81% |
26CDNA | CAREDX INC | Healthcare | $4.19B | 0.69% |
27TARS | TARSUS PHARMACEUTICALS INC | Healthcare | $3.79B | 0.62% |
28ARQT | ARCUTIS BIOTHERAPEUTICS INC | Healthcare | $3.48B | 0.57% |
29WRBY | WARBY PARKER INC | Healthcare | $3.32B | 0.54% |
30NHC | NATIONAL HEALTHCARE CORP | Healthcare | $3.30B | 0.54% |
31IRTC | IRHYTHM HOLDINGS INC | Healthcare | $3.15B | 0.51% |
32ACAD | ACADIA PHARMACEUTICALS INC | Healthcare | $3.14B | 0.51% |
33GRDN | GUARDIAN PHARMACY SERVICES INC | Healthcare | $3.13B | 0.51% |
34XERS | XERIS BIOPHARMA HOLDINGS INC | Healthcare | $3.04B | 0.50% |
35ATRC | ATRICURE INC | Healthcare | $2.85B | 0.47% |
36SUPN1 | SUPERNUS PHARMACEUTICALS INC | Healthcare | $2.11B | 0.35% |
37ESTA | ESTABLISHMENT LABS HOLDINGS INC | Healthcare | $2.05B | 0.33% |
38BCRX | BIOCRYST PHARMACEUTICALS INC | Healthcare | $1.98B | 0.32% |
39ETON | ETON PHARMACEUTICALS INC | Healthcare | $1.77B | 0.29% |
40INSP | INSPIRE MEDICAL SYSTEMS INC | Healthcare | $1.75B | 0.29% |
41NRIX | NURIX THERAPEUTICS INC | Healthcare | $1.70B | 0.28% |
42RARE | ULTRAGENYX PHARMACEUTICAL INC | Healthcare | $1.66B | 0.27% |
43TDOC | TELADOC HEALTH INC | Healthcare | $1.58B | 0.26% |
44WGS | GENEDX HOLDINGS CORP | Healthcare | $1.55B | 0.25% |
45ANAB | ANAPTYSBIO INC | Healthcare | $1.43B | 0.23% |
46NVCR | NOVOCURE LTD | Healthcare | $1.37B | 0.22% |
47STAA | STAAR SURGICAL CO | Healthcare | $1.34B | 0.22% |
48URGN | UROGEN PHARMA LTD | Healthcare | $1.29B | 0.21% |
49TNDM | TANDEM DIABETES CARE INC | Healthcare | $1.22B | 0.20% |
50ATEC | ALPHATEC HOLDINGS INC | Healthcare | $1.10B | 0.18% |
51IRMD | IRADIMED CORP | Healthcare | $1.09B | 0.18% |
52SIBN | SI-BONE INC | Healthcare | $1.09B | 0.18% |
53CSTL | CASTLE BIOSCIENCES INC | Healthcare | $1.06B | 0.17% |
54HROW | HARROW INC | Healthcare | $1.06B | 0.17% |
55CBLL | CERIBELL INC | Healthcare | $1.02B | 0.17% |
56BVS | BIOVENTUS INC | Healthcare | $915M | 0.15% |
57OMDA | OMADA HEALTH INC | Healthcare | $912M | 0.15% |
58MGTX | MEIRAGTX HOLDINGS PLC | Healthcare | $844M | 0.14% |
59PHR | PHREESIA INC | Healthcare | $783M | 0.13% |
60DCTH | DELCATH SYSTEMS INC | Healthcare | $744M | 0.12% |
61SGHT | SIGHT SCIENCES INC | Healthcare | $611M | 0.10% |
62TCMD | TACTILE SYSTEMS TECHNOLOGY INC | Healthcare | $601M | 0.10% |
63NRC | NRC HEALTH | Healthcare | $565M | 0.09% |
64MYGN | MYRIAD GENETICS INC | Healthcare | $545M | 0.09% |
65RCEL | AVITA MEDICAL INC | Healthcare | $509M | 0.08% |
66PHAT | PHATHOM PHARMACEUTICALS INC | Healthcare | $506M | 0.08% |
67ANGO | ANGIODYNAMICS INC | Healthcare | $504M | 0.08% |
68EOLS | EVOLUS INC | Healthcare | $475M | 0.08% |
69PBYI | PUMA BIOTECHNOLOGY INC | Healthcare | $418M | 0.07% |
70NPCE | NEUROPACE INC | Healthcare | $413M | 0.07% |
71FENC | FENNEC PHARMACEUTICALS INC | Healthcare | $382M | 0.06% |
72TMCI | TREACE MEDICAL CONCEPTS INC | Healthcare | $350M | 0.06% |
73VMD | VIEMED HEALTHCARE INC | Healthcare | $345M | 0.06% |
74AGEN | AGENUS INC | Healthcare | $311M | 0.05% |
75SMTI | SANARA MEDTECH INC | Healthcare | $299M | 0.05% |
76INFU | INFUSYSTEM HOLDINGS INC | Healthcare | $296M | 0.05% |
77OFIX | ORTHOFIX MEDICAL INC | Healthcare | $283M | 0.05% |
78SPOK | SPOK HOLDINGS INC | Healthcare | $243M | 0.04% |
79ELMD | ELECTROMED INC | Healthcare | $204M | 0.03% |
80INGN | INOGEN INC | Healthcare | $146M | 0.02% |
81CUE | CUE BIOPHARMA INC | Healthcare | $127M | 0.02% |
82BDSX | BIODESIX INC | Healthcare | $109M | 0.02% |
83NRXS | NEURAXIS INC | Healthcare | $82M | 0.01% |
84GOSS | GOSSAMER BIO INC | Healthcare | $69M | 0.01% |
Full long-leg book as of November 2026 · cap-weighted · total market cap $611.43B. Hypothetical model holdings — not a registered fund’s portfolio.
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 465-name universe at November 2026. Rows: Large ≥ $4.2B, Small < $1.1B. Columns: Value ≥ 0.67, Growth < 0.36 B/M. The dot marks the capital-weighted centroid of the book — 94% toward Large, 69% toward Growth. +5% unclassified (16 missing size/value). Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1998 → November 2026; the right-hand end is the same value as the box’s dot. 84 names now. Hypothetical holdings — descriptive, not P&L.
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
No verdict sits within 1.0pp of its limit.
Data version — panel=20261113T032607 rows=2198308 asof=202611 issuers=20261113T032403 rates=20261113T032429
Measured on the 2026-11 formation date across 84 holdings (cap-weighted). A different formation date can produce different verdicts.
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 335 monthly observations · about 3.4 in the 99% tail · paired percentile bootstrap over months
The estimators differ materially in value but agree on the verdict. Historical and Gaussian fund VaR differ by 33%; both still land on the same side of the 2x limit.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Did the edge survive the paper coming out?
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 13.0% | -11.3% |
| 3 yearsp.a. | 21.9% | -9.5% |
| 5 yearsp.a. | 15.4% | 4.9% |
| 10 yearsp.a. | 14.0% | 1.4% |
| Since inceptionp.a. | 9.3% | 0.5% |
| Year | Long leg | Long-short |
|---|---|---|
| 202611 mo | 20.6% | -6.1% |
| 2025 | 19.5% | -7.7% |
| 2024 | 19.4% | 11.5% |
| 2023 | 22.5% | -5.3% |
| 2022 | -6.9% | 19.0% |
| 2021 | 14.5% | 87.9% |
| 2020 | 19.9% | -14.7% |
| 2019 | 20.9% | -31.6% |
| 2018 | -2.3% | 25.4% |
| 2017 | 16.7% | -28.0% |
| 2016 | -11.9% | 12.6% |
| 2015 | 5.9% | -2.4% |
| 2014 | 33.2% | -2.3% |
| 2013 | 28.0% | -9.4% |
| 2012 | 20.3% | 2.7% |
| 2011 | 10.3% | 14.1% |
| 2010 | 9.0% | -6.2% |
| 2009 | 8.8% | -17.7% |
| 2008 | -14.5% | 49.4% |
| 2007 | 1.2% | 1.5% |
| 2006 | 12.3% | 15.7% |
| 2005 | 1.0% | 21.6% |
| 2004 | 17.0% | 4.7% |
| 2003 | 15.0% | -27.2% |
| 2002 | -21.9% | 56.1% |
| 2001 | -12.1% | 6.1% |
| 2000 | 41.9% | -64.8% |
| 1999 | 1.1% | 27.7% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through November 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
The Foundry Healthcare Gross Profitability Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a Gross Profitability signal and holds the top quintile with the highest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.